Psychedelics hold promise for primary care research
Family Practice – January 24, 2022
Source: OpenAlex
Summary
A "psychedelic renaissance" is transforming medicine, renewing interest in hallucinogens like psilocybin, mescaline, and lysergic acid diethylamide. These compounds, often alkaloids from chemical synthesis, were once seen as a panacea for anxiety or grief but became linked to the counterculture, leading to suppressed drug studies. Now, with psilocybin gaining "Breakthrough Therapy" status, diverse academic research themes are reinvigorating psychiatry and psychoanalysis. Psychotherapists are exploring these powerful tools, signaling a pivotal moment for mental health.
Abstract
Dear Editor, We are in the midst of a so-called “psychedelic renaissance,” a time of renewed interest in the therapeutic potential of psychoactive drugs such as psilocybin, mescaline, and lysergic acid diethylamide. When they first emerged as topics of academic interest in the mid-20th century, these substances were greeted with exuberance for their apparent panacea-like effects in treating a range of conditions from depression and anxiety to post-traumatic stress disorder to existential grief in terminal cancer patients. Despite their promise, these compounds became associated with the counterculture movement in the public imagination and research was suppressed by political forces aligned with the so-called “War on Drugs.” It seems, however, that we have reached a watershed moment as psychedelic research has reemerged and even become mainstream, reaching the front page of the New York Times in May of this year.1 Already, psilocybin has been granted “Breakthrough Therapy” status by the...